Teva Pharmaceutical Industries Ltd. $TEVA Stock Position Reduced by Carnegie Lake Advisors LLC

Key Points

• Carnegie Lake Advisors cut its Teva stake by 96.9% in the third quarter, selling 94,820 shares and retaining 3,080 shares valued at about $122,000.
• Teva’s latest quarterly results beat estimates: earnings were $0.86 per share versus $0.72 expected, and revenue was $4.39 billion versus $4.23 billion expected, though revenue fell 1.9% year over year.
• Analyst sentiment was broadly positive, with a “Moderate Buy” consensus and an average price target of $47.23; the article also reports recent insider share sales.

Carnegie Lake Advisors LLC lessened its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 96.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,080 shares of the company's stock after selling 94,820 shares during the quarter. Carnegie Lake Advisors LLC's holdings in Teva Pharmaceutical Industries were worth $122,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in TEVA. WCM Investment Management LLC boosted its stake in shares of Teva Pharmaceutical Industries by 191.4% during the 1st quarter. WCM Investment Management LLC now owns 40,820,600 shares of the company's stock worth $1,157,264,000 after purchasing an additional 26,813,522 shares during the last quarter. SEB Asset Management AB purchased a new stake in shares of Teva Pharmaceutical Industries during the first quarter worth about $59,551,000. Assenagon Asset Management S.A. grew its holdings in shares of Teva Pharmaceutical Industries by 128.1% during the second quarter. Assenagon Asset Management S.A. now owns 3,056,017 shares of the company's stock worth $103,538,000 after buying an additional 1,716,315 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. raised its position in shares of Teva Pharmaceutical Industries by 2.2% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 45,956,714 shares of the company's stock valued at $1,384,216,000 after buying an additional 1,004,941 shares during the last quarter. Finally, Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD acquired a new position in shares of Teva Pharmaceutical Industries in the second quarter valued at approximately $33,799,000. Institutional investors and hedge funds own 54.05% of the company's stock.

Insider Buying and Selling

In related news, Director Roberto Mignone sold 367,600 shares of the business's stock in a transaction that occurred on Friday, September 18th. The shares were sold at an average price of $39.06, for a total value of $14,358,456.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Brian Savage sold 7,342 shares of the business's stock in a transaction that occurred on Friday, September 18th. The shares were sold at an average price of $38.85, for a total transaction of $285,236.70. Following the completion of the sale, the insider owned 8,500 shares of the company's stock, valued at approximately $330,225. The trade was a 46.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 420,942 shares of company stock valued at $16,572,473. Insiders own 0.54% of the company's stock.

Teva Pharmaceutical Industries News Summary

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Teva’s third-quarter earnings beat estimates, and the company raised its 2026 revenue and product-sales outlook, citing strong branded-drug sales. Revenue was slightly lower year over year, but the results and upgraded outlook were encouraging. Article: Teva Q3 Earnings Beat Estimates, 2026 Revenue View Raised, Stock Up
• Positive Sentiment: A report highlighted 33% sales growth last quarter across Teva’s three key branded medicines, alongside improved margins and net-debt reduction—factors that could strengthen earnings and the balance sheet. Article: Teva's 3 Key Branded Drugs Grew Sales 33% Last Quarter
• Positive Sentiment: Leerink Partners raised its price target to $52 from $45 and maintained an “outperform” rating, signaling greater analyst confidence in potential upside. Article: Leerink Partners Raises Teva Price Target
• Positive Sentiment: HC Wainwright reiterated a “Buy” rating with a $52 target and projected 2027 EPS of $3.03, well above its 2026 estimate of $1.94. Teva analyst estimates
• Negative Sentiment: Insider Mark Sabag sold 46,000 shares for about $1.93 million, reducing his direct holdings by 36.29%. Insider sales can weigh on sentiment, though they do not necessarily indicate a change in the company’s outlook. SEC insider transaction filing

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on TEVA shares. Oppenheimer upped their price objective on shares of Teva Pharmaceutical Industries from $50.00 to $52.00 and gave the company an "outperform" rating in a research note on Friday, October 9th. Barclays lifted their target price on shares of Teva Pharmaceutical Industries from $42.00 to $47.00 and gave the stock an "overweight" rating in a research note on Thursday, October 15th. Wall Street Zen downgraded Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a report on Sunday, July 12th. TD Cowen boosted their price target on Teva Pharmaceutical Industries from $55.00 to $57.00 and gave the company a "buy" rating in a report on Wednesday, November 4th. Finally, Leerink Partners increased their price target on Teva Pharmaceutical Industries from $45.00 to $52.00 and gave the stock an "outperform" rating in a research note on Thursday. Thirteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $47.23.

Teva Pharmaceutical Industries Stock Down 0.2%

Shares of NYSE:TEVA opened at $42.52 on Monday. The company has a current ratio of 0.95, a quick ratio of 0.74 and a debt-to-equity ratio of 1.59. The firm has a market cap of $49.55 billion, a price-to-earnings ratio of 98.88, a PEG ratio of 4.00 and a beta of 0.97. The stock's 50-day moving average price is $39.49 and its two-hundred day moving average price is $34.79. Teva Pharmaceutical Industries Ltd. has a 12-month low of $23.61 and a 12-month high of $43.34.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings data on Tuesday, November 3rd. The company reported $0.86 EPS for the quarter, beating analysts' consensus estimates of $0.72 by $0.14. The company had revenue of $4.39 billion during the quarter, compared to the consensus estimate of $4.23 billion. Teva Pharmaceutical Industries had a net margin of 2.94% and a return on equity of 33.20%. The company's quarterly revenue was down 1.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.78 EPS. On average, research analysts forecast that Teva Pharmaceutical Industries Ltd. will post 1.98 EPS for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas.

Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.

Teva is headquartered in Tel Aviv, Israel.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.